Safety of targeting tumor endothelial cell antigens

Hdl Handle:
http://hdl.handle.net/11285/612242
Title:
Safety of targeting tumor endothelial cell antigens
Authors:
Wagner, Samuel C.; Riordan, Neil H.; Ichim, Thomas E.; Szymanski, Julia; Ma, Hong; Perez, Jesus A.; López, Javier; Plata Muñoz, Juan J. ( 0000-0003-0293-1135 ) ; Silva, Francisco; Patel, Amit N.; Kesari, Santosh
Issue Date:
2016-04-12
Publisher:
Springer Open
Abstract:
Abstract The mechanisms underlying discrimination between “self” and “non-self”, a central immunological principle, require careful consideration in immune oncology therapeutics where eliciting anti-cancer immunity must be weighed against the risk of autoimmunity due to the self origin of tumors. Whole cell vaccines are one promising immunotherapeutic avenue whereby a myriad of tumor antigens are introduced in an immunogenic context with the aim of eliciting tumor rejection. Despite the possibility collateral damage to healthy tissues, cancer immunotherapy can be designed such that off target autoimmunity remains limited in scope and severity or completely non-existent. Here we provide an immunological basis for reconciling the safety of cancer vaccines, focusing on tumor endothelial cell vaccines, by discussing the following topics: (a) Antigenic differences between neoplastic and healthy tissues that can be leveraged in cancer vaccine design; (b) The layers of tolerance that control T cell responses directed against antigens expressed in healthy tissues and tumors; and, (c) The hierarchy of antigenic epitope selection and display in response to whole cell vaccines, and how antigen processing and presentation can afford a degree of selectivity against tumors. We conclude with an example of early clinical data utilizing ValloVax™, an immunogenic placental endothelial cell vaccine that is being advanced to target the tumor endothelium of diverse cancers, and we report on the safety and efficacy of ValloVax™ for inducing immunity against tumor endothelial antigens.
Discipline:
Ciencias de la Salud / Health Sciences
Additional Links:
http://www.ncbi.nlm.nih.gov/pubmed/27071457
Type:
Artículo / Article
Appears in Collections:
Springer/BMC

Full metadata record

DC FieldValue Language
dc.contributor.authorWagner, Samuel C.en
dc.contributor.authorRiordan, Neil H.en
dc.contributor.authorIchim, Thomas E.en
dc.contributor.authorSzymanski, Juliaen
dc.contributor.authorMa, Hongen
dc.contributor.authorPerez, Jesus A.en
dc.contributor.authorLópez, Javieren
dc.contributor.authorPlata Muñoz, Juan J.en
dc.contributor.authorSilva, Franciscoen
dc.contributor.authorPatel, Amit N.en
dc.contributor.authorKesari, Santoshen
dc.date.accessioned2016-06-08T17:19:38Z-
dc.date.available2016-06-08T17:19:38Z-
dc.date.issued2016-04-12-
dc.identifier.pmid27071457-
dc.identifier.otherJournal of Translational Medicine. 2016 Apr 12;14(1):90-
dc.identifier.urihttp://dx.doi.org/10.1186/s12967-016-0842-8-
dc.identifier.urihttp://hdl.handle.net/11285/612242-
dc.description.abstractAbstract The mechanisms underlying discrimination between “self” and “non-self”, a central immunological principle, require careful consideration in immune oncology therapeutics where eliciting anti-cancer immunity must be weighed against the risk of autoimmunity due to the self origin of tumors. Whole cell vaccines are one promising immunotherapeutic avenue whereby a myriad of tumor antigens are introduced in an immunogenic context with the aim of eliciting tumor rejection. Despite the possibility collateral damage to healthy tissues, cancer immunotherapy can be designed such that off target autoimmunity remains limited in scope and severity or completely non-existent. Here we provide an immunological basis for reconciling the safety of cancer vaccines, focusing on tumor endothelial cell vaccines, by discussing the following topics: (a) Antigenic differences between neoplastic and healthy tissues that can be leveraged in cancer vaccine design; (b) The layers of tolerance that control T cell responses directed against antigens expressed in healthy tissues and tumors; and, (c) The hierarchy of antigenic epitope selection and display in response to whole cell vaccines, and how antigen processing and presentation can afford a degree of selectivity against tumors. We conclude with an example of early clinical data utilizing ValloVax™, an immunogenic placental endothelial cell vaccine that is being advanced to target the tumor endothelium of diverse cancers, and we report on the safety and efficacy of ValloVax™ for inducing immunity against tumor endothelial antigens.en
dc.language.isoenen
dc.publisherSpringer Openen
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/27071457en
dc.rightsOpen Access-
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleSafety of targeting tumor endothelial cell antigensen
dc.typeArtículo / Articleen
dc.identifier.pmcidPMC4830034-
dc.rights.holderWagner et al.-
dc.date.updated2016-06-01T12:19:19Z-
dc.subject.disciplineCiencias de la Salud / Health Sciences-
All Items in REPOSITORIO DEL TECNOLOGICO DE MONTERREY are protected by copyright, with all rights reserved, unless otherwise indicated.